Scholarlink

<p>Currently reported survival outcomes for gliomas exhibit significant variability and controversy. In this study, we aim to provide survival data in Chinese populations by conducting a retrospective analysis of management and survival trends in a large cohort of glioma patients from a single institute in China. A total of 1206 patients with newly diagnosed gliomas treated between 2000 and 2020 were enrolled, including 537 glioblastoma (WHO grade 4), 450 astrocytomas (grade 2/3) and 219 oligodendroglial tumors (grade 2/3). The estimated overall survival at 5 years was 18.9% for glioblastoma, 58.8% for astrocytomas, and 80.7% for oligodendroglial tumors, while median survival was 17.2 months, 82.8 months, and not reached, respectively. The survival trend has increased over the past decades for all types of gliomas. Additionally, similar survival trends were observed between grade 2 and 3 IDH-mutant gliomas. Rising trends were observed in patients undergoing postsurgical radiation and chemotherapy. Multivariate analysis identified adjuvant radiochemotherapy as an independent factor for better prognosis in glioblastoma and astrocytomas. In summary, despite its retrospective nature, this cohort of glioma patients exhibits favorable survival outcomes compared to global statistics, indicating a geographical disparity in glioma prognosis. The promotion of adjuvant chemoradiotherapy contributes to improved prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Management and survival trends for diffuse gliomas diagnosed at a single neurooncology center in China during 2000 to 2020

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月12日

查看全文
  • Depei Li,
  • Yinsheng Chen,
  • Tang-Fai Wong,
  • Qunying Yang,
  • ChengCheng Guo,
  • Xiaobing Jiang,
  • Chao Ke,
  • Xiangheng Zhang,
  • Jing Zeng,
  • Yanchun Lv,
  • Shaoxiong Wu,
  • Jian Wang,
  • Ke Sai,
  • Yonggao Mou,
  • Zhongping Chen

摘要

Currently reported survival outcomes for gliomas exhibit significant variability and controversy. In this study, we aim to provide survival data in Chinese populations by conducting a retrospective analysis of management and survival trends in a large cohort of glioma patients from a single institute in China. A total of 1206 patients with newly diagnosed gliomas treated between 2000 and 2020 were enrolled, including 537 glioblastoma (WHO grade 4), 450 astrocytomas (grade 2/3) and 219 oligodendroglial tumors (grade 2/3). The estimated overall survival at 5 years was 18.9% for glioblastoma, 58.8% for astrocytomas, and 80.7% for oligodendroglial tumors, while median survival was 17.2 months, 82.8 months, and not reached, respectively. The survival trend has increased over the past decades for all types of gliomas. Additionally, similar survival trends were observed between grade 2 and 3 IDH-mutant gliomas. Rising trends were observed in patients undergoing postsurgical radiation and chemotherapy. Multivariate analysis identified adjuvant radiochemotherapy as an independent factor for better prognosis in glioblastoma and astrocytomas. In summary, despite its retrospective nature, this cohort of glioma patients exhibits favorable survival outcomes compared to global statistics, indicating a geographical disparity in glioma prognosis. The promotion of adjuvant chemoradiotherapy contributes to improved prognosis.